Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
Completed · Phase 2 · Has a placebo group
Conditions studied: Respiratory Syncytial Virus Infection
In brief
The primary objective of this study is to evaluate the effect of presatovir on respiratory syncytial virus (RSV) viral load in autologous or allogeneic hematopoietic cell transplant (HCT) recipients with an acute RSV lower respiratory tract infection (LRTI).
Key facts
- Study ID
- NCT02254421
- Run by
- Gilead Sciences
- People needed
- 60
- Starts
- 2015-01-31
- Expected to finish
- 2017-04-17
- Last updated by the study team
- 2018-09-24
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope — Duarte, California, United States
- University of Chicago — Chicago, Illinois, United States
- John Hopkins — Baltimore, Maryland, United States
- Dana Farber Cancer Institute — Boston, Massachusetts, United States
- University of Michigan — Ann Arbor, Michigan, United States
- University of Minnesota — Minneapolis, Minnesota, United States
- New York Weill Cornell Medical Center — New York, New York, United States
- Duke University — Durham, North Carolina, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- Fred Hutchison Cancer Research Center — Seattle, Washington, United States
- Medical College of Wisconsin — Milwaukee, Wisconsin, United States
- Hopital Saint-Louis, APHP — Paris, France
- Hopital Foch — Suresnes, France
- CHU de Bordeaux — Talence, France
- Seoul Saint Mary's Hospital — Seoul, South Korea
- Karolinska Institutet — Stockholm, Sweden
- University Clinical Basel — Basel, Switzerland
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.